What is the typical intramuscular (IM) testosterone dose for a patient with hypogonadism (low testosterone levels)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 9, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Intramuscular Testosterone Dosing for Low Testosterone (100s ng/dL)

For men with testosterone levels in the 100s ng/dL, start with 50-100 mg of intramuscular testosterone cypionate or enanthate weekly, or 100-200 mg every 2 weeks, with the weekly regimen providing more stable serum levels. 1, 2, 3

Standard Dosing Regimens

The FDA-approved dosing for testosterone cypionate is 50-400 mg administered every 2-4 weeks for hypogonadal replacement 3. However, clinical practice has evolved toward more frequent administration:

  • Weekly dosing: 50-100 mg provides more stable testosterone levels and is preferred over biweekly administration 1, 2
  • Biweekly dosing: 100-200 mg every 2 weeks is the traditional approach but causes significant fluctuations in serum testosterone 2, 4
  • Starting dose: 50 mg weekly is reasonable for initial therapy, with dose adjustments based on follow-up levels 1, 5

Dose Titration Strategy

Begin with 50-100 mg weekly and measure testosterone levels 2-3 months after initiation, targeting mid-normal values (approximately 400-700 ng/dL) 1, 2. For injectable formulations, check levels midway between injections 1, 2. Adjust the dose in 25-50 mg increments based on these results and clinical response 1.

Important Clinical Considerations

Injection Frequency Matters

Weekly injections produce more stable serum testosterone levels compared to biweekly administration, which results in supraphysiological peaks followed by subtherapeutic troughs 2, 4. These fluctuations may contribute to:

  • Mood swings and variable sexual function 4
  • Greater cardiovascular risk compared to transdermal preparations 1, 2
  • Higher rates of erythrocytosis 1

Monitoring Requirements

  • Initial monitoring: Check testosterone levels at 2-3 months after starting or changing doses 1
  • Ongoing monitoring: Once stable, monitor every 6-12 months 1
  • Additional surveillance: Monitor hematocrit/hemoglobin and PSA levels regularly 2
  • Timing of blood draw: Obtain levels midway between injections for accurate assessment 1, 2

Alternative Considerations

Subcutaneous administration of testosterone cypionate or enanthate at 50-100 mg weekly is an effective alternative that may offer:

  • Lower estradiol and hematocrit elevations compared to intramuscular injections 6
  • Easier self-administration with less discomfort 5, 7
  • More stable serum testosterone levels between doses 7, 8

Common Pitfalls to Avoid

Do not use biweekly dosing if the patient experiences mood fluctuations or symptoms returning before the next injection - this indicates the need for weekly administration 2, 4. The large fluctuations in testosterone levels with biweekly injections (100-200 mg every 2 weeks) can cause unsatisfactory shifts in mood and sexual function 4.

Do not neglect cardiovascular risk assessment before initiating therapy, as testosterone may increase cardiovascular events in high-risk patients 1, 2. Injectable testosterone may carry greater cardiovascular risk than transdermal preparations, possibly due to fluctuating levels 1, 2.

Do not assume normal liver enzymes rule out significant liver disease - men with diabetes or metabolic syndrome require screening for liver fibrosis even with normal transaminases 9.

References

Guideline

Testosterone Enanthate Conversion Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Testosterone Cypionate Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Testosterone therapy--what, when and to whom?

The aging male : the official journal of the International Society for the Study of the Aging Male, 2004

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.